Chemomab Therapeutics (NASDAQ:CMMB) Price Target Raised to $7.00

Chemomab Therapeutics (NASDAQ:CMMB) had its price target increased by analysts at Maxim Group from $4.00 to $7.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Maxim Group’s price target suggests a potential upside of 296.60% from the company’s current price.

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $11.00 target price (down previously from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th.

Chemomab Therapeutics Stock Performance

CMMB stock traded down $0.14 during trading on Thursday, reaching $1.77. 425,368 shares of the company traded hands, compared to its average volume of 541,611. Chemomab Therapeutics has a 12 month low of $0.58 and a 12 month high of $2.55. The business has a 50 day simple moving average of $1.97 and a 200 day simple moving average of $1.70. The company has a market capitalization of $25.35 million, a price-to-earnings ratio of -1.75 and a beta of 0.66.

Institutional Trading of Chemomab Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Sphera Funds Management LTD. acquired a new stake in shares of Chemomab Therapeutics in the third quarter worth approximately $1,907,000. XTX Topco Ltd boosted its stake in Chemomab Therapeutics by 63.8% during the fourth quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after buying an additional 9,706 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Chemomab Therapeutics during the fourth quarter worth $26,000. 46.05% of the stock is owned by institutional investors and hedge funds.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).